Crossject annonce l’initiation de la couverture de son titre par ODDO BHF Recommandation « Surperformance » avec un objectif de cours de 7,10 € Les analystes citent le contrat de 60 millions de dollars entre Crossject et la BARDA pour le ZEPIZURE ® comme une validation...

Crossject to present at Biotech Showcase on January 9 at 16:30 PT   Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company...

Vivacitas Oncology to Present AR-67 at the Biotech Showcase Investor Conference WALNUT CREEK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately held clinical stage biopharmaceutical company focused on tough-to-treat...

Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...

Zomedica Pharmaceuticals Corp. To Present at 2017 Biotech Showcase Conference ANN ARBOR, Mich., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced that it will present at...